Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Sunitinib, and Cyclophosphamide for Stage IV Ocular Melanoma
NCT00482911Phase 2Terminated
- Sponsor
- National Institutes of Health
- Start
- Apr 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide and sunitinib in Ocular melanoma (OM) (2 cohorts), sponsored by National Institutes of Health. Primary endpoints: Response Rate (Complete and Partial Response) at 2 years, Toxicity at 16 months and 1 more. Started Apr 2007; status: terminated.
02
Drugs
lenalidomidesunitinib
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT00482911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482911.